Data Sharing Solutions for Biobanks for the COVID-19 Pandemic.

IF 1.2 4区 生物学 Q4 CELL BIOLOGY
Biopreservation and Biobanking Pub Date : 2020-12-01 Epub Date: 2020-08-19 DOI:10.1089/bio.2020.0040
Shonali Paul, Mrinal Kanti Chatterjee
{"title":"Data Sharing Solutions for Biobanks for the COVID-19 Pandemic.","authors":"Shonali Paul,&nbsp;Mrinal Kanti Chatterjee","doi":"10.1089/bio.2020.0040","DOIUrl":null,"url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) is a novel illness, which is not fully understood. Whether an individual has traveled outside their respective country or never left their community, COVID-19 is a highly contagious illness, which can result in high death rates. Biobanks will play a role in providing tools to examine data from those receiving treatment along with reviewing the current and long treatment outcomes associated with this novel coronavirus disease. A diverse, global network made up of laboratory scientists, clinical researchers, epidemiologists, data science teams, physicians, and so on must have a standardized, collaborative, virtual biobanking solution to share clinical expertise and evidence-based solutions. This virtual biobank must be centrally managed to ensure standardized quality assurance and quality control efforts. Virtual biobanks will eliminate the need to transport samples between two locations for a specific study, minimizing the risk of contamination. It is necessary for virtual biobanks to upload imaging data from those patients diagnosed with COVID-19. Standardized, collected information will be essential in the area of discovery and validation of disease markers as well as novel therapeutic strategies. It is essential for biobanks to collect COVID-19 specimens along with corresponding clinical and demographic data from COVID-19 diagnostic testing. Because COVID-19 is an acute respiratory illness, proper collection procedures must be in place to collect respiratory samples for biobanking purposes. A preconfigured purpose-built COVID-19 Laboratory Information Management System (LIMS) is an efficient tool to seamlessly manage a data sharing network. Data entered into LIMS will be beneficial in designing much needed clinical trials to address any unmet needs to better address clinical treatment and outcomes. The partners or entities associated with the COVID-19 data sharing network will be able to effectively communicate, view data, and images associated with their respective research interest to advance COVID-19 research and data driven, clinical care.</p>","PeriodicalId":49231,"journal":{"name":"Biopreservation and Biobanking","volume":" ","pages":"581-586"},"PeriodicalIF":1.2000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/bio.2020.0040","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biopreservation and Biobanking","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/bio.2020.0040","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/8/19 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 8

Abstract

The coronavirus disease 2019 (COVID-19) is a novel illness, which is not fully understood. Whether an individual has traveled outside their respective country or never left their community, COVID-19 is a highly contagious illness, which can result in high death rates. Biobanks will play a role in providing tools to examine data from those receiving treatment along with reviewing the current and long treatment outcomes associated with this novel coronavirus disease. A diverse, global network made up of laboratory scientists, clinical researchers, epidemiologists, data science teams, physicians, and so on must have a standardized, collaborative, virtual biobanking solution to share clinical expertise and evidence-based solutions. This virtual biobank must be centrally managed to ensure standardized quality assurance and quality control efforts. Virtual biobanks will eliminate the need to transport samples between two locations for a specific study, minimizing the risk of contamination. It is necessary for virtual biobanks to upload imaging data from those patients diagnosed with COVID-19. Standardized, collected information will be essential in the area of discovery and validation of disease markers as well as novel therapeutic strategies. It is essential for biobanks to collect COVID-19 specimens along with corresponding clinical and demographic data from COVID-19 diagnostic testing. Because COVID-19 is an acute respiratory illness, proper collection procedures must be in place to collect respiratory samples for biobanking purposes. A preconfigured purpose-built COVID-19 Laboratory Information Management System (LIMS) is an efficient tool to seamlessly manage a data sharing network. Data entered into LIMS will be beneficial in designing much needed clinical trials to address any unmet needs to better address clinical treatment and outcomes. The partners or entities associated with the COVID-19 data sharing network will be able to effectively communicate, view data, and images associated with their respective research interest to advance COVID-19 research and data driven, clinical care.

针对COVID-19大流行的生物银行数据共享解决方案。
2019冠状病毒病(COVID-19)是一种尚未完全了解的新型疾病。无论一个人是否离开过自己的国家,还是从未离开过自己的社区,COVID-19都是一种高度传染性疾病,可能导致高死亡率。生物银行将发挥作用,提供工具来检查接受治疗的人的数据,并审查与这种新型冠状病毒疾病相关的当前和长期治疗结果。一个由实验室科学家、临床研究人员、流行病学家、数据科学团队、医生等组成的多元化全球网络必须有一个标准化的、协作的虚拟生物银行解决方案,以共享临床专业知识和基于证据的解决方案。这个虚拟生物库必须集中管理,以确保标准化的质量保证和质量控制工作。虚拟生物库将消除在两个地点之间运送样本进行特定研究的需要,将污染风险降至最低。虚拟生物银行有必要上传新冠肺炎患者的影像数据。标准化的、收集的信息在发现和确认疾病标志物以及新的治疗策略方面至关重要。生物库必须收集COVID-19标本以及相应的COVID-19诊断检测的临床和人口统计数据。由于COVID-19是一种急性呼吸道疾病,因此必须制定适当的收集程序,收集用于生物库目的的呼吸道样本。预先配置的专用COVID-19实验室信息管理系统(LIMS)是无缝管理数据共享网络的有效工具。输入LIMS的数据将有助于设计急需的临床试验,以解决任何未满足的需求,从而更好地解决临床治疗和结果。与COVID-19数据共享网络相关的合作伙伴或实体将能够有效沟通、查看与其各自研究兴趣相关的数据和图像,以推进COVID-19研究和数据驱动的临床护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biopreservation and Biobanking
Biopreservation and Biobanking CELL BIOLOGY-MEDICAL LABORATORY TECHNOLOGY
CiteScore
3.30
自引率
12.50%
发文量
114
审稿时长
6-12 weeks
期刊介绍: Biopreservation and Biobanking is the first journal to provide a unifying forum for the peer-reviewed communication of recent advances in the emerging and evolving field of biospecimen procurement, processing, preservation and banking, distribution, and use. The Journal publishes a range of original articles focusing on current challenges and problems in biopreservation, and advances in methods to address these issues related to the processing of macromolecules, cells, and tissues for research. In a new section dedicated to Emerging Markets and Technologies, the Journal highlights the emergence of new markets and technologies that are either adopting or disrupting the biobank framework as they imprint on society. The solutions presented here are anticipated to help drive innovation within the biobank community. Biopreservation and Biobanking also explores the ethical, legal, and societal considerations surrounding biobanking and biorepository operation. Ideas and practical solutions relevant to improved quality, efficiency, and sustainability of repositories, and relating to their management, operation and oversight are discussed as well.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信